Oculus Innovative Sciences, Inc. (NASDAQ: OCLS)
Shares of OCLS are trading higher in the premarket on news that the company had received a new U.S. patent for the use of Microcyn technology hypochlorous acid in the treatment and mitigation of atopic dermatitis.
The Senior Vice President of Research and Development for Oculus, Bob Northey noted:
“Our intellectual property portfolio is perfectly synced with our new focus on the dermatology market with our direct sales force. The empirical evidence demonstrating Microcyn’s efficacy in the treatment of atopic dermatitis is highly compelling. This new patent provides Oculus market exclusivity for the use of hypochlorous acid with broad ranges of activity in the treatment of atopic dermatitis until the year 2027 when the patent expires.”
OCLS has been consolidating since a recent move higher in the month of June on high relative volume and has demanded the attention from active traders due to its low float and ability to put in strong moves.
About Oculus Innovative Sciences, Inc.
Oculus Innovative Sciences, Inc., incorporated on November 20, 2006, is a global healthcare company that designs, produces, and markets prescription and non-prescription products in over 20 countries. The Company’s focus is on the commercialization of its technology platform called Microcyn Technology. This technology is based on electrically charged oxychlorine small molecules designed to target a wide range of organisms that cause disease (pathogens). Outside the United States, its Microcyn Technology products have a CE Mark device approval in Europe for debriding, irrigating and moistening acute and chronic wounds in comprehensive wound treatment by reducing microbial load and creating a moist environment. Reuters
